PDF(1251 KB)
CCLG-ALL2008方案治疗10岁以上儿童及青少年急性淋巴细胞白血病的疗效分析
兰洋, 陈晓娟, 邹尧, 阮敏, 竺晓凡
中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (5) : 405-410.
PDF(1251 KB)
PDF(1251 KB)
CCLG-ALL2008方案治疗10岁以上儿童及青少年急性淋巴细胞白血病的疗效分析
Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged > 10 years with acute lymphoblastic leukemia
目的 探讨CCLG-ALL2008方案治疗10岁以上儿童及青少年初诊急性淋巴细胞白血病（ALL）的长期疗效。方法 收集2008年4月至2015年4月采用CCLG-ALL2008方案治疗的150例10岁以上ALL患儿的临床资料，采用Kaplan-Meier生存分析评估患儿总体生存（OS）率和无事件生存（EFS）率。结果 150例患儿中，男87例（58.0%），女63例（42.0%），中位年龄11（10~15）岁；中危患儿84例（56.0%），高危患儿66例（44.0%）；B-ALL患儿122例（81.3%），T-ALL患儿28例（18.7%）；融合基因检测阳性51例（34.0%），其中BCR-ABL阳性16例（31%），TEL-AML1阳性11例（22%），E2A-PBX1阳性8例（16%），其他基因阳性16例（31%）。采用CCLG-ALL2008方案治疗1个疗程完全缓解率为96.0%（144/150）。150例患儿中位随访时间为52（3~122）个月，5年OS率为79.0%±3.5%，5年EFS率为67.3%±4.1%。中危患儿和高危患儿，以及B-ALL患儿和T-ALL患儿间5年OS率及5年EFS率比较，差异均无统计学意义（P > 0.05）。诱导治疗结束时骨髓达完全缓解患儿的5年OS率及5年EFS率均高于骨髓未达完全缓解者（P < 0.05）。结论 10岁以上儿童及青少年ALL患儿采用CCLG-ALL2008方案治疗，其完全缓解率高，5年OS率及EFS率均较高。诱导治疗后未达到完全缓解患儿预后不良。
Objective To study the long-term clinical effect of CCLG-ALL2008 regimen in the treatment of children and adolescents, aged > 10 years, with newly diagnosed acute lymphoblastic leukemia (ALL). Methods A retrospective analysis was performed for the clinical data of 150 ALL children and adolescents aged > 10 years who were treated with CCLG-ALL2008 regimen from April 2008 to April 2015. The Kaplan-Meier method was used to analyze overall survival (OS) rate and event-free survival (EFS) rate. Results Among the 150 children and adolescents, there were 87 (58.0%) boys and 63 (42.0%) girls, with a median age of 11 years (range 10-15 years). Of the 150 children and adolescents, 84 (56.0%) had intermediate risk and 66 (44.0%) had high risk; 122 (81.3%) had B-lineage acute lymphoblastic leukemia (B-ALL) and 28 (18.7%) had T-lineage acute lymphoblastic leukemia (T-ALL). The fusion gene test yielded positive results in 51 children and adolescents (34.0%), among whom 16 (31%) had positive BCR-ABL, 11 (22%) had positive TEL-AML1, 8 (16%) had positive E2A-PBX1, and 16 (31%) were positive for other fusion genes. The complete remission rate was 96.0% (144/150) after one course of treatment with CCLG-ALL2008 regimen. The median follow-up time was 52 months (range 3-122 months). The 5-year OS rate was 79.0%±3.5%, and the 5-year EFS rate was 67.3%±4.1%. There were no significant differences in 5-year OS and EFS rates between the children with intermediate or high risk, as well as between the children with B-ALL or T-ALL (P > 0.05). The children and adolescents who achieved complete remission of bone marrow at the end of induction therapy had significantly higher 5-year OS and EFS rates than those who did not achieve complete remission (P < 0.05). Conclusions In ALL children and adolescents aged > 10 years, CCLG-ALL2008 regimen can help to achieve high complete remission rate, 5-year OS rate and 5-year EFS rate. The children and adolescents failing to achieve complete remission at the end of induction therapy tend to have a poor prognosis.
急性淋巴细胞白血病 / CCLG-ALL2008方案 / 生存率 / 儿童 / 青少年
Acute lymphoblastic leukemia / CCLG-ALL2008 regimen / Survival rate / Child / Adolescent
[1] Pui CH. Recent research advances in childhood acute lymphoblastic leukemia[J]. J Formos Med Assoc, 2010, 109(11):777-787.
[2] Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia:progress through collaboration[J]. J Clin Oncol, 2015, 33(27):2938-2948.
[3] 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9):641-644.
[4] Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, et al. Acute lymphoblastic leukemia in children and adolescents:prognostic factors and analysis of survival[J]. Rev Bras Hematol Hemoter, 2015, 37(4):223-229.
[5] Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts[J]. Haematologica, 2013, 98(11):1702-1710.
[6] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版. 北京:科学出版社, 2007:131-134.
[7] Gao C, Zhao XX, Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts:a single institutional study of 1,004 patients[J]. Am J Hematol, 2012, 87(11):1022-1027.
[8] 刘凯奇, 赵邢力, 魏辉, 等. 青少年急性淋巴细胞白血病单中心临床研究[J]. 中华内科杂志, 2016, 55(2):102-106.
[9] 叶启东, 汤静燕, 潘慈, 等. 10岁以上儿童、青少年急性淋巴细胞白血病的临床研究[J]. 中华血液学杂志, 2011, 32(12):840-843.
[10] 吴珺, 陆爱东, 张乐萍. 10岁以上儿童青少年急性淋巴细胞白血病的临床特点及预后分析[J]. 中国当代儿科杂志, 2017, 19(6):614-619.
[11] Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia:results in 3184 patients of the AIEOP-BFM ALL 2000 study[J]. Blood, 2010, 115(16):3206-3214.
[12] Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia[J]. J Clin Oncol, 2011, 29(4):386-391.
[13] Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols[J]. J Clin Oncol, 2007, 25(7):813-819.
[14] Hochberg J, Khaled S, Forman SJ, et al. Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission[J]. Br J Haematol, 2013, 161(1):27-42.
[15] Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia[J]. Leukemia, 2008, 22(4):771-782.
[16] Athale UH, Gibson PJ, Bradley NM, et al. Minimal residual disease and childhood leukemia:standard of care recommendations from the pediatric oncology group of ontario MRD working group[J]. Pediatr Blood Cancer, 2016, 63(6):973-982.
国家自然科学基金（81470339）。
